BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lowered by State of Alaska Department of Revenue

State of Alaska Department of Revenue trimmed its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 25.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,730 shares of the biotechnology company's stock after selling 7,495 shares during the period. State of Alaska Department of Revenue's holdings in BioMarin Pharmaceutical were worth $1,428,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of BioMarin Pharmaceutical by 56.1% in the 3rd quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 281 shares during the last quarter. CWM LLC increased its holdings in shares of BioMarin Pharmaceutical by 363.1% in the 3rd quarter. CWM LLC now owns 11,106 shares of the biotechnology company's stock valued at $781,000 after acquiring an additional 8,708 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in shares of BioMarin Pharmaceutical by 437.5% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,720 shares of the biotechnology company's stock valued at $121,000 after acquiring an additional 1,400 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of BioMarin Pharmaceutical by 87.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 16,663 shares of the biotechnology company's stock valued at $1,171,000 after acquiring an additional 7,760 shares during the last quarter. Finally, Creative Planning increased its holdings in shares of BioMarin Pharmaceutical by 20.9% in the 3rd quarter. Creative Planning now owns 14,300 shares of the biotechnology company's stock valued at $1,005,000 after acquiring an additional 2,475 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock traded up $0.43 during trading on Friday, hitting $64.85. The stock had a trading volume of 1,048,855 shares, compared to its average volume of 1,674,690. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The firm has a market cap of $12.36 billion, a P/E ratio of 38.83, a PEG ratio of 0.57 and a beta of 0.28. The business has a fifty day moving average of $64.86 and a two-hundred day moving average of $71.47. BioMarin Pharmaceutical Inc. has a fifty-two week low of $60.63 and a fifty-two week high of $94.85.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BMRN shares. UBS Group upped their price objective on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lowered their price objective on BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating for the company in a research note on Wednesday, October 30th. Royal Bank of Canada restated a "sector perform" rating and set a $80.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 30th. Cantor Fitzgerald restated an "overweight" rating and set a $90.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, December 12th. Finally, Robert W. Baird lowered their price objective on BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating for the company in a research note on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $94.20.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.